Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Crews

Showing results (111-120 of 173) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemiaJun J Yang, Wendy Landier, Wenjian Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium studyLars M Wagner, Judith G Villablanca, Clinton F Stewart, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2013
Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustmentsJennifer L Pauley, John C Panetta, Kristine R Crews, et al.
Clinical Pharmacology and Therapeutics|October 30, 2020
Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic LeukemiaChuang Jiang, Wenjian Yang, Takaya Moriyama, et al.
Pharmacogenomics|August 2, 2014
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypesJ Kevin Hicks, Kristine R Crews, Patricia Flynn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumorsWayne L Furman, Kristine R Crews, Catherine Billups, et al.
Clinical Pharmacology and Therapeutics|January 25, 2014
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 updateK R Crews, A Gaedigk, H M Dunnenberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2022
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline UpdateSharon H Giordano, Maria Alice B Franzoi, Sarah Temin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2022
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline UpdateNaren Ramakrishna, Carey K Anders, Nancy U Lin, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 30, 2011
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemiaAmit K Mitra, Kristine R Crews, Stanley Pounds, et al.
Pageof 18

Showing results (111-120 of 173) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemiaJun J Yang, Wendy Landier, Wenjian Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium studyLars M Wagner, Judith G Villablanca, Clinton F Stewart, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2013
Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustmentsJennifer L Pauley, John C Panetta, Kristine R Crews, et al.
Clinical Pharmacology and Therapeutics|October 30, 2020
Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic LeukemiaChuang Jiang, Wenjian Yang, Takaya Moriyama, et al.
Pharmacogenomics|August 2, 2014
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypesJ Kevin Hicks, Kristine R Crews, Patricia Flynn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumorsWayne L Furman, Kristine R Crews, Catherine Billups, et al.
Clinical Pharmacology and Therapeutics|January 25, 2014
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 updateK R Crews, A Gaedigk, H M Dunnenberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2022
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline UpdateSharon H Giordano, Maria Alice B Franzoi, Sarah Temin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2022
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline UpdateNaren Ramakrishna, Carey K Anders, Nancy U Lin, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 30, 2011
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemiaAmit K Mitra, Kristine R Crews, Stanley Pounds, et al.
Pageof 18